EpiAxis Therapeutics is a pre-clinical stage Australian epigenetics company focused on the development of novel first in class oncology therapeutics. Epigenetics is an emerging and active therapeutic area and offers the prospect of a less toxic cancer treatment by re-programming both cancer and immune cells for superior outcomes.

Our inhibitors block nuclear translocation of LSD1 and we are the only company to exploit this discovery, making our assets first in class. This has also provided us with a robust intellectual property portfolio with 11 patent families covering combination use of LSD1 inhibitors as a class as well as composition of matter patents in all major geographies.